Seraxis

Seraxis company information, Employees & Contact Information

Explore related pages

Related company profiles:

Seraxis is bringing transformative therapies to the millions of people worldwide struggling with the management of insulin-requiring diabetes and the associated life-threatening complications. Seraxis’ lead program, SR-02, is a novel islet replacement therapy for patients of insulin-requiring diabetes with concurrent immunosuppression therapy. This therapy is the foundation of Seraxis follow-on therapies for patients without immune suppression. Frazier Life Sciences, Polaris Partners, Eli Lilly and Company, the T1D Fund and others are investors in Seraxis.

Company Details

Employees
26
Founded
-
Address
20400 Century Blvd,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Germantown, Maryland
Looking for a particular Seraxis employee's phone or email?

Seraxis Questions

News

Seraxis Announces Closing of $40M Series C Financing Round - BioBuzz

Seraxis Announces Closing of $40M Series C Financing Round BioBuzz

Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes - Newswire.com

Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes Newswire.com

Seraxis Appoints Paul Strum as Chief Medical Officer - citybiz

Seraxis Appoints Paul Strum as Chief Medical Officer citybiz

Seraxis diabetes stem cell programme meets GMP audit standards - Cleanroom Technology

Seraxis diabetes stem cell programme meets GMP audit standards Cleanroom Technology

Seraxis’ Manufacturing Suite Completes GMP Quality System Audit Ahead of SR-02 IND Filing and Transplantation of Pancreatic Clusters to Patients With Type 1 Diabetes - Newswire.com

Seraxis’ Manufacturing Suite Completes GMP Quality System Audit Ahead of SR-02 IND Filing and Transplantation of Pancreatic Clusters to Patients With Type 1 Diabetes Newswire.com

Seraxis Presents Successful Results Using Synthetic Replacement Endocrine Clusters for Type 1 Diabetes at the 4th IPITA / HSCI / JDRF Summit - Yahoo Finance

Seraxis Presents Successful Results Using Synthetic Replacement Endocrine Clusters for Type 1 Diabetes at the 4th IPITA / HSCI / JDRF Summit Yahoo Finance

Seraxis gains IND clearance for islet replacement therapy - BioWorld MedTech

Seraxis gains IND clearance for islet replacement therapy BioWorld MedTech

Seraxis appoints Shelley Hartman, Jerry Baty and MJ Choi to the Board of Directors - BioSpace

Seraxis appoints Shelley Hartman, Jerry Baty and MJ Choi to the Board of Directors BioSpace

Top Seraxis Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant